Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Celgene Corp.
Sponsor

Celgene Corp.

United States Route 206 And Province Line Road, 08543-4000, United States

About the sponsor

Celgene Corp. funds extensive research in acute myeloid leukemia, myelodysplastic syndromes, and myeloid malignancies, with additional activity in myeloproliferative neoplasms and myelofibrosis. Its trial portfolio also includes studies in multiple myeloma and other plasma cell disorders, reflecting a major focus on refractory and relapsed blood cancers.

  • Acute myeloid leukemia
  • Myelodysplastic syndromes
  • Multiple myeloma
  • Myelofibrosis
  • Myeloid malignancies

Research in this area also extends to anemia linked with marrow failure and clonal blood disorders.

About Specializations

Celgene Corp. runs clinical trials in conditions such as Plasma cell myeloma, Plasma cell myeloma refractory, Myelofibrosis, Myelodysplastic syndrome, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

36 clinical trials

Plasma cell myeloma refractory

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celgene Corp.

Follicular lymphoma

Recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Plasma cell myeloma refractory

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Central nervous system lymphoma+4

Recruiting
Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Celgene Corp.

Anaemia+4

Recruiting
Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Plasma cell myeloma

Recruiting
Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Celgene Corp.

Plasma cell myeloma refractory

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Thalassaemia beta

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Malignant lymphoid neoplasm

Recruiting
InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Plasma cell myeloma

Recruiting
Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Autoimmune haemolytic anaemia+3

Not yet recruiting
InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.